Atrial fibrillation in the 21st century: A current understanding of risk factors and primary prevention strategies

Mayo Clinic Proceedings

Volumn 88, Issue 4, 2013, Pages 394-409

  Menezes, Arthur R ^a   Lavie, Carl J ^a,b   DiNicolantonio, James J ^c   O'Keefe, James ^d   Morin, Daniel P ^a   Khatib, Sammy ^a   Milani, Richard V ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

^c Wegmans Pharmacy   (United States)

^d SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAFFEINE; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; LOSARTAN; METOPROLOL; NICOTINIC ACID; OMEGA 3 FATTY ACID; PLACEBO; SPIRONOLACTONE; VALSARTAN; VITAMIN D;

ALCOHOL ABUSE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DISEASE ASSOCIATION; DRUG MEGADOSE; DYSLIPIDEMIA; EMBOLISM; EXERCISE; HEART ATRIUM FIBRILLATION; HEART FUNCTION; HUMAN; HYPERTENSION; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PATHOGENESIS; REVIEW; RISK FACTOR; SLEEP DISORDERED BREATHING;

EID: 84876564215     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2013.01.022     Document Type: Review

References (172)

1. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98(10): 946-952. (Pubitemid 28446646)
2. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285(18):2370-2375. (Pubitemid 32424106)
3. Miyasaka Y, Barnes ME, Gersh BJ, et al. Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation. 2006;114(2):119-125. (Pubitemid 44420743)
4. Kannel WB, Wolf PA, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998; 82(8A):2N-9N. (Pubitemid 28507114)
5. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statisticse2011 update: a report from the American Heart Association. Circulation. 2011;123(4):e18-e209.
6. Menezes AR, Artham S, Lavie CJ, Khatib S. Anticoagulation strategies in atrial fibrillation. Rev Cardiovasc Med. 2012; 13(1):e1-e13.
7. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991;22(8):983-988.
8. Rosiak M, Dziuba M, Chudzik M, et al. Risk factors for atrial fibrillation: not always severe heart disease, not always so "lonely." Cardiol J. 2010;17(5):437-442.
9. Gutierrez C, Blanchard DG. Atrial fibrillation: diagnosis and treatment. Am Fam Physician. 2011;83(1):61-68.
10. Schnabel RB. Can we predict the occurrence of atrial fibrillation? Clin Cardiol. 2012;35(suppl 1):5-9.
11. Fox CS, Parise H, D'Agostino RB Sr, et al. Parental atrial fibrillation as a risk factor for atrial fibrillation in offspring. JAMA. 2004;291(23):2851-2855. (Pubitemid 38747806)
12. Arnar DO, Thorvaldsson S, Manolio TA, et al. Familial aggregation of atrial fibrillation in Iceland. Eur Heart J. 2006;27(6): 708-712.
13. Parvez B, Darbar D. The "missing" link in atrial fibrillation heritability. J Electrocardiol. 2011;44(6):641-644.
14. Lubitz SA, Ozcan C, Magnani JW, Kääb S, Benjamin EJ, Ellinor PT. Genetics of atrial fibrillation: implications for future research directions and personalized medicine. Circ Arrhythm Electrophysiol. 2010;3(3):291-299.
15. Ellinor PT, Yoerger DM, Ruskin JN, MacRae CA. Familial aggregation in lone atrial fibrillation. Hum Genet. 2005;118(2): 179-184. (Pubitemid 41672080)
16. Darbar D, Herron KJ, Ballew JD, et al. Familial atrial fibrillation is a genetically heterogeneous disorder. J Am Coll Cardiol. 2003; 41(12):2185-2192. (Pubitemid 36724265)
17. Christophersen IE, Ravn LS, Budtz-Joergensen E, et al. Familial aggregation of atrial fibrillation: a study in Danish twins. Circ Arrhythm Electrophysiol. 2009;2(4):378-383.
18. Furberg CD, Psaty BM, Manolio TA, Gardin JM, Smith VE, Rautaharju PM. Prevalence of atrial fibrillation in elderly subjects (the Cardiovascular Health Study). Am J Cardiol. 1994; 74(3):236-241. (Pubitemid 24239044)
19. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med. 1995; 155(5):469-473.
20. Friberg J, Scharling H, Gadsboll N, Jensen GB. Sex-specific increase in the prevalence of atrial fibrillation (The Copenhagen City Heart Study). Am J Cardiol. 2003;92(12):1419-1423. (Pubitemid 37532563)
21. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the Anticoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001; 285(18):2370-2375. (Pubitemid 32424106)
22. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Crit Pathw Cardiol. 2005;4(4):198-203. (Pubitemid 41697502)
23. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: finding from the third National Health and Nutrition Examination Survey. JAMA. 2002; 287(3):356-359. (Pubitemid 34251969)
24. Tanner RM, Baber U, Carson AP, et al. Association of the metabolic syndrome with atrial fibrillation among United States adults (from the REasons for Geographic and Racial Differences in Stroke [REGARDS] Study). Am J Cardiol. 2011;108(2):227-232.
25. Watanabe H, Tanabe N, Watanabe T, et al. Metabolic syndrome and risk of development of atrial fibrillation: the Niigata preventive medicine study. Circulation. 2008;117(10):1255-1260. (Pubitemid 351365676)
26. Chamberlain AM, Agarwal SK, Ambrose M, Folsom AR, Soliman EZ, Alonso A. Metabolic syndrome and incidence of atrial fibrillation among blacks and whites in the Atherosclerosis Risk in Communities (ARIC) Study. Am Heart J. 2010; 159(5):850-856.
27. Mohanty S, Mohanty P, Di Biase L, et al. Impact of metabolic syndrome on procedural outcomes in patients with atrial fibrillation undergoing catheter ablation. J Am Coll Cardiol. 2012;59(14):1295-1301.
28. Lavie CJ, Milani RV, Ventura HO. Obesity and cardiovascular disease: risk factor, paradox, and impact of weight loss. J Am Coll Cardiol. 2009;53(21):1925-1932.
29. Rosengren A, Hauptman PJ, Lappas G, Olsson L, Wilhelmsen L, Swedberg K. Big men and atrial fibrillation: effects of body size and weight gain on risk of atrial fibrillation in men. Eur Heart J. 2009;30(9):1113-1120.
30. Frost L, Hune LJ, Vestergaard P. Overweight and obesity as risk factors for atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Med. 2005;118(5):489-495. (Pubitemid 40615472)
31. Vaziri SM, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation: the Framingham Heart Study. Circulation. 1994;89(2):724.
32. Patel DA, Lavie CJ, Milani RV, Ventura HO. Left atrial volume index predictive of mortality independent of left ventricular geometry in a large clinical cohort with preserved ejection fraction. Mayo Clin Proc. 2011;86(8):730-737.
33. Pritchett AM, Jacobsen SJ, Mahoney DW, Rodeheffer RJ, Bailey KR, Redfield MM. Left atrial volume as an index of left atrial size: a population-based study. J Am Coll Cardiol. 2003;41(6):1036.
34. Gerdts E, Oikarinen L, Palmieri V, et al. Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study. Hypertension. 2002;39(3):739-743. (Pubitemid 34252867)
35. Patel DA, Lavie CJ, Milani RV, Gilliland Y, Shah S, Ventura HO. Association of left ventricular geometry with left atrial enlargement in patients with preserved ejection fraction [published online November 9, 2011]. Congest Heart Fail. http://dx.doi.org/10.1111/j.1751-7133.2011.00264.x.
36. Cil H, Bulur S, Türker Y, et al. Impact of body mass index on left ventricular diastolic dysfunction [published online April 4, 2012]. Echocardiography. http://dx.doi.org/10.1111/j.1540-8175..01688.
37. Russo C, Jin Z, Homma S, et al. Effect of obesity and overweight on left ventricular diastolic function: a communitybased study in an elderly cohort. J Am Coll Cardiol. 2011; 57(12):1368-1374.
38. Tsang TS, Gersh BJ, Appleton CP, et al. Left ventricular diastolic dysfunction as a predictor of the first diagnosed nonvalvular atrial fibrillation in 840 elderly men and women. J Am Coll Cardiol. 2002;40(9):1636-1644. (Pubitemid 35253642)
39. Wang TJ, Parise H, Levy D, et al. Obesity and the risk of newonset atrial fibrillation. JAMA. 2004;292(20):2471-2477. (Pubitemid 39552671)
40. Wanahita N, Messerli FH, Bangalore S, Gami AS, Somers VK, Steinberg JS. Atrial fibrillation and obesity: results of a metaanalysis. Am Heart J. 2008;155(2):310-315.
41. Tedrow UB, Conen D, Ridker PM, et al. The long-and shortterm impact of elevated body mass index on the risk of new atrial fibrillation: the WHS (Women's Health Study). J Am Coll Cardiol. 2010;55(21):2319-2327.
42. Tsang TS, Barnes ME, Miyasaka Y, et al. Obesity as a risk factor for the progression of paroxysmal to permanent atrial fibrillation: a longitudinal cohort study of 21 years. Eur Heart J. 2008; 29(18):2227-2233.
43. Guglin M, Maradia K, Chen R, Curtis AB. Relation of obesity to recurrence rate and burden of atrial fibrillation. Am J Cardiol. 2011;107(4):579-582.
44. Weijs B, de Vos CB, Limantoro I, Cheriex EC, Tieleman RG, Crijns HJ. The presence of an atrial electromechanical delay in idiopathic atrial fibrillation as determined by tissue Doppler imaging. Int J Cardiol. 2012;156(1):121-122.
45. Yagmur J, Cansel M, Acikgoz N, et al. Assessment of atrial electromechanical delay by tissue Doppler echocardiography in obese subjects. Obesity (Silver Spring). 2011;19(4):779-783.
46. Aksnes TA, Schmieder RE, Kjeldsen SE, Ghani S, Hua TA, Julius S. Impact of new-onset diabetes mellitus on development of atrial fibrillation and heart failure in high-risk hypertension (from the VALUE Trial). Am J Cardiol. 2008;101(5):634-638. (Pubitemid 351625088)
47. Dublin S, Glazer NL, Smith NL, et al. Diabetes mellitus, glycemic control, and risk of atrial fibrillation. J Gen Intern Med. 2010;25(8):853-858.
48. Du X, Ninomiya T, de Galan B, et al. Risks of cardiovascular events and effects of routine blood pressure lowering among patients with type 2 diabetes and atrial fibrillation: results of the ADVANCE study. Eur Heart J. 2009;30(9):1128-1135.
49. Wilhelmsen L, Rosengren A, Lappas G. Hospitalizations for atrial fibrillation in the general male population: morbidity and risk factors. J Intern Med. 2001;250(5):382-389. (Pubitemid 32989592)
50. Benjamin EJ, Levy D, Vaziri SM, D'Agostino RB, Belanger AJ, Wolf PA. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. JAMA. 1994;271(11):840-844.
51. Schnabel RB, Sullivan LM, Levy D, et al. Development of a risk score for atrial fibrillation (Framingham Heart Study): a community-based cohort study. Lancet. 2009;373(9665):739-745.
52. Ruigómez A, Johansson S, Wallander MA, Rodríguez LA. Incidence of chronic atrial fibrillation in general practice and its treatment pattern. J Clin Epidemiol. 2002;55(4):358-363. (Pubitemid 34245363)
53. Ostgren CJ, Merlo J, Råstam L, Lindblad U. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes Obes Metab. 2004;6(5):367-374. (Pubitemid 39172859)
54. Watanabe H, Tanabe N, Yagihara N, Watanabe T, Aizawa Y, Kodama M. Association between lipid profile and risk of atrial fibrillation. Circ J. 2011;75(12):2767-2774.
55. Haywood LJ, Ford CE, Crow RS, et al. Atrial fibrillation at baseline and during follow-up in ALLHAT (Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial). J Am Coll Cardiol. 2009;54(22):2023-2031.
56. Lopez FL, Agarwal SK, Maclehose RF, et al. Blood lipid levels, lipid-lowering medications, and the incidence of atrial fibrillation: the Atherosclerosis Risk in Communities Study. Circ Arrhythm Electrophysiol. 2012;5(1):155-162.
57. Komatsu T, Tachibana H, Sato Y, Ozawa M, Kunugita F, Nakamura M. Long-term efficacy of upstream therapy with lipophilic or hydrophilic statins on antiarrhythmic drugs in patients with paroxysmal atrial fibrillation: comparison between atorvastatin and pravastatin. Int Heart J. 2011;52(6):359-365.
58. Fang WT, Li HJ, Zhang H, et al. The role of statin therapy in the prevention of atrial fibrillation: a meta-analysis of randomized controlled trials [published online February 29, 2012]. Br J Clin Pharmacol. http://dx.doi.org/10.1111/j.1365-2125.2012.04258.
59. Rahimi K, Emberson J, McGale P, et al. Effect of statins on atrial fibrillation: collaborative meta-analysis of published and unpublished evidence from randomised controlled trials [published online March 16, 2011]. BMJ. http://dx.doi.org/10./bmj.d1250.
60. Dentali F, Gianni M, Squizzato A, et al. Use of statins and recurrence of atrial fibrillation after catheter ablation or electrical cardioversion: a systematic review and meta-analysis. Thromb Haemost. 2011;106(2):363-370.
61. Bhardwaj A, Sood NA, Kluger J, Coleman CI. Lack of effect of statins on maintenance of normal sinus rhythm following electrical cardioversion of persistent atrial fibrillation. Int J Clin Pract. 2010;64(8):1116-1120.
62. Gbadebo TD, Okafor H, Darbar D. Differential impact of race and risk factors on incidence of atrial fibrillation. Am Heart J. 2011;162(1):31-37.
63. Go O, Rosendorff C. Hypertension and atrial fibrillation. Curr Cardiol Rep. 2009;11(6):430-435.
64. Mitchell GF, Vasan RS, Keyes MJ, et al. Pulse pressure and risk of new-onset atrial fibrillation. JAMA. 2007;297(7): 709-715. (Pubitemid 46294560)
65. Psaty BM, Manolio TA, Kuller LH, et al. Incidence of and risk factors for atrial fibrillation in older adults. Circulation. 1997; 96(7):2455-2461. (Pubitemid 27425856)
66. Minami M, Kobayashi Y, Toyokawa S, Inoue K, Takeshita Y. Risk factors for new-onset atrial fibrillation during routine medical checkups of Japanese male workers. Int Heart J. 2009;50(4):457-464.
67. Conen D, Tedrow UB, Koplan BA, Glynn RJ, Buring JE, Albert CM. Influence of systolic and diastolic blood pressure on the risk of incident atrial fibrillation in women. Circulation. 2009;119(16):2146-2152.
68. Thomas MC, Dublin S, Kaplan RC, Glynn RJ, Buring JE, Albert CM. Blood pressure control and risk of incident atrial fibrillation. Am J Hypertens. 2008;21(10):1111-1116.
69. Rosario IC. Obstructive sleep apnea: a review and update. Minn Med. 2011;94(11):44-48.
70. Gami AS, Hodge DO, Herges RM, et al. Obstructive sleep apnea, obesity, and the risk of incident atrial fibrillation. J Am Coll Cardiol. 2007;49(5):565-571. (Pubitemid 46177437)
71. Asirvatham SJ, Kapa S. Sleep apnea and atrial fibrillation: the autonomic link. J Am Coll Cardiol. 2009;54(22):2084-2086.
72. Gami AS, Pressman G, Caples SM, et al. Association of atrial fibrillation and obstructive sleep apnea. Circulation. 2004; 110(4):364-367. (Pubitemid 38993843)
73. Dimitri H, Ng M, Brooks AG, et al. Atrial remodeling in obstructive sleep apnea: implications for atrial fibrillation. Heart Rhythm. 2012;9(3):321-327.
74. Rajagopalan N. Obstructive sleep apnea: not just a sleep disorder. J Postgrad Med. 2011;57(2):168-175.
75. Linz D, Schotten U, Neuberger HR, Böhm M, Wirth K. Negative tracheal pressure during obstructive respiratory events promotes atrial fibrillation by vagal activation. Heart Rhythm. 2011;8(9):1436-1443.
76. Svatikova A, Wolk R, Shamsuzzaman AS, Kara T, Olson EJ, Somers VK. Serum amyloid a in obstructive sleep apnea. Circulation. 2003;108(12):1451-1454. (Pubitemid 37176450)
77. Shamsuzzaman AS, Winnicki M, Lanfranchi P, et al. Elevated C-reactive protein in patients with obstructive sleep apnea. Circulation. 2002;105(21):2462-2464. (Pubitemid 34568964)
78. Hartmann G, Tschop M, Fischer R, et al. High altitude increases circulating interleukin-6, interleukin-1 receptor antagonist and C-reactive protein. Cytokine. 2000;12(3): 246-252. (Pubitemid 30449882)
79. Monahan K, Brewster J, Wang L, et al. Relation of the severity of obstructive sleep apnea in response to anti-arrhythmic drugs in patients with atrial fibrillation or atrial flutter. Am J Cardiol. 2012;110(3):369-372.
80. Ng CY, Liu T, Shehata M, Stevens S, Chugh SS, Wang X. Meta-analysis of obstructive sleep apnea as predictor of atrial fibrillation recurrence after catheter ablation. Am J Cardiol. 2011;108(1):47-51.
81. Matiello M, Nadal M, Tamborero D, et al. Low efficacy of atrial fibrillation ablation in severe obstructive sleep apnoea patients. Europace. 2010;12(8):1084-1089.
82. Abe H, Takahashi M, Yaegashi H, et al. Efficacy of continuous positive airway pressure on arrhythmias in obstructive sleep apnea patients. Heart Vessels. 2010;25(1):63-69.
83. Kanagala R, Murali NS, Friedman PA, et al. Obstructive sleep apnea and the recurrence of atrial fibrillation. Circulation. 2003;107(20):2589-2594. (Pubitemid 36628941)
84. Balbão CE, de Paola AA, Fenelon G. Effects of alcohol on atrial fibrillation. Ther Adv Cardiovasc Dis. 2009;3(1):53-63.
85. Ettinger PO, Wu CF, De La Cruz C, Weisse AB, Ahmed SS, Regan TJ. Arrhythmias and the "Holiday Heart": alcoholassociated cardiac rhythm disorders. Am Heart J. 1978;95(5): 555-562. (Pubitemid 8329576)
86. Menz V, Grimm W, Hoffmann J, Maisch B. Alcohol and rhythm disturbance: the holiday heart syndrome. Herz. 1996;21(4):227-231. (Pubitemid 26267726)
87. Lowenstein SR, Gabow PA, Cramer J, Oliva PB, Ratner K. The role of alcohol in new-onset atrial fibrillation. Arch Intern Med. 1983;143(10):1882- 1885. (Pubitemid 13007914)
88. Samokhvalov AV, Irving HM, Rehm J. Alcohol consumption as a risk factor for atrial fibrillation: a systematic review and metaanalysis. Eur J Cardiovasc Prev Rehabil. 2010;17(6):706-712.
89. Djoussé L, Levy D, Benjamin EJ, et al. Long-term alcohol consumption and the risk of atrial fibrillation in the Framingham Study. Am J Cardiol. 2004;93(6):710-713. (Pubitemid 38338559)
90. Conen D, Tedrow UB, Cook NR, Moorthy MV, Buring JE, Albert CM. Alcohol consumption and risk of incident atrial fibrillation in women. JAMA. 2008;300(21):2489-2496.
91. Mukamal KJ, Tolstrup JS, Friberg J, Jensen G, Grønbaek M. Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation. 2005;112(12):1736-1742. (Pubitemid 41368149)
92. Kodama S, Saito K, Tanaka S, et al. Alcohol consumption and risk of atrial fibrillation: a meta-analysis. J Am Coll Cardiol. 2011; 57(4):427-436.
93. O'Keefe JH, Bybee KA, Lavie CJ. Alcohol and cardiovascular health: the razor-sharp double-edged sword. J Am Coll Cardiol. 2007;50(11):1009-1014. (Pubitemid 47348233)
94. Menezes AR, Lavie CJ, Milani RV, Arena RA, Church TS. Cardiac rehabilitation and exercise therapy in the elderly: should we invest in the aged? J Geriatr Cardiol. 2012;9(1):68-75.
95. Lavie CJ, Thomas RJ, Squires RW, Allison TG, Milani RV. Exercise training and cardiac rehabilitation in primary and secondary prevention of coronary heart disease. Mayo Clin Proc. 2009;84(4):373-383.
96. Mont L, Tamborero D, Elosua R, et al. Physical activity, height, and left atrial size are independent risk factors for lone atrial fibrillation in middle-aged healthy individuals. Europace. 2008; 10(1):15-20. (Pubitemid 351767264)
97. Molina L, Mont L, Marrugat J, et al. Long-term endurance sport practice increases the incidence of lone atrial fibrillation in men: a follow-up study. Europace. 2008;10(5):618-623. (Pubitemid 351775294)
98. O'Keefe JH, Patil HR, Lavie CJ, Magalski A, Vogel RA, McCullough PA. Potential adverse cardiovascular effects from excessive endurance exercise. Mayo Clin Proc. 2012; 87(6):587-595.
99. Patil HR, O'Keefe JH, Lavie CJ, Magalski A, Vogel RA, McCullough PA. Cardiovascular damage resulting from chronic excessive endurance exercise. Mo Med. 2012;109(4):312-321.
100. Link MS, Homoud MK, Wang PJ, Estes NA III. Cardiac arrhythmias in the athlete: the evolving role of electrophysiology. Curr Sports Med Rep. 2002;1(2):75-85.
101. Karjalainen J, Kujala UM, Kaprio J, Sarna S, Viitasalo M. Lone atrial fibrillation in vigorously exercising middle aged men: case-control study. BMJ. 1998;316(7147):1784-1785. (Pubitemid 28269153)
102. Elosua R, Arquer A, Mont L, et al. Sport practice and the risk of lone atrial fibrillation: a case-control study. Int J Cardiol. 2006;108(3):332-337. (Pubitemid 43339799)
103. Baldesberger S, Bauersfeld U, Candinas R, et al. Sinus node disease and arrhythmias in the long-term follow-up of former professional cyclists. Eur Heart J. 2008;29(1):71-78.
104. Artin B, Singh M, Richeh C, Jawad E, Arora R, Khosla S. Caffeine-related atrial fibrillation. Am J Ther. 2010;17(5): e169-e171.
105. Patil H, Lavie CJ, O'Keefe JH. Cuppa joe: friend or foe? effects of chronic coffee consumption on cardiovascular and brain health. Mo Med. 2011;108(6):431-438.
106. Frost L, Vestergaard P. Caffeine and risk of atrial fibrillation or flutter: the Danish Diet, Cancer, and Health Study. Am J Clin Nutr. 2005;81(3):578-582.
107. Zeng X, Li Q, Zhang M, Wang W, Tan X. Green tea may be benefit to the therapy of atrial fibrillation. J Cell Biochem. 2011; 112(7):1709-1712.
108. Rashid A, Hines M, Scherlag BJ, Yamanashi WS, Lovallo W. The effects of caffeine on the inducibility of atrial fibrillation. J Electrocardiol. 2006;39(4):421-425. (Pubitemid 44441350)
109. Di Rocco JR, During A, Morelli PJ, Heyden M, Biancaniello TA. Atrial fibrillation in healthy adolescents after highly caffeinated beverage consumption: two case reports. J Med Case Rep. 2011;5:18.
110. Conen D, Chiuve SE, Everett BM, Zhang SM, Buring JE, Albert CM. Caffeine consumption and incident atrial fibrillation in women. Am J Clin Nutr. 2010;92(3):509-514.
111. Klatsky AL, Hasan AS, Armstrong MA, Udaltsova N, Morton C. Coffee, caffeine, and risk of hospitalization for arrhythmias. Perm J. 2011;15(3):19-25.
112. Lavie CJ, Lee JH, Milani RV. Vitamin D and cardiovascular disease: will it live up to its hype? J Am Coll Cardiol. 2011;58(15): 1547-1556.
113. O'Keefe JH, Lavie CJ, Holick MF. Vitamin D supplementation for cardiovascular disease prevention. JAMA. 2011;306(14): 1546-1547.
114. O'Keefe JH, Carter MD, Lavie CJ. Primary and secondary prevention of cardiovascular diseases: a practical evidence-based approach. Mayo Clin Proc. 2009;84(8):741-757.
115. Wang L, Manson JE, Buring JE, Lee IM, Sesso HD. Dietary intake of dairy products, calcium, and vitamin D and the risk of hypertension in middle-aged and older women. Hypertension. 2008;51(4):1073-1079. (Pubitemid 351398988)
116. Pilz S, Tomaschitz A, März W. Vitamin D deficiency and stroke: time to act!. Am J Cardiol. 2010;106(11):1674.
117. Drechsler C, Pilz S, Obermayer-Pietsch B, et al. Vitamin D deficiency is associated with sudden cardiac death, combined cardiovascular events, and mortality in haemodialysis patients. Eur Heart J. 2010;31(18):2253-2261.
118. Lee JH, Gadi R, Spertus JA, Tang F, O'Keefe JH. Prevalence of vitamin D deficiency in patients with acute myocardial infarction. Am J Cardiol. 2011;107(11):1636-1638.
119. McGreevy C, Williams D. New insights about vitamin D and cardiovascular disease: a narrative review. Ann Intern Med. 2011;155(12):820-826.
120. Rienstra M, Cheng S, Larson MG, et al. Vitamin D status is not related to development of atrial fibrillation in the community. Am Heart J. 2011;162(3):538-541.
121. Hoang MT, Defina LF, Willis BL, Leonard DS, Weiner MF, Brown ES. Association between low serum 25-hydroxyvitamin D and depression in a large sample of healthy adults: the Cooper Center longitudinal study. Mayo Clin Proc. 2011; 86(11):1050-1055.
122. O'Keefe JH, Patil HR, Lavie CJ. Can vitamin D deficiency break your heart? Mayo Clin Proc. 2012;87(4):412-413.
123. Lavie CJ, DiNicolantonio JJ, O'Keefe JH, Milani RV. Vitamin D status, left ventricular geometric abnormalities, and cardiovascular disease [published online November 2, 2012]. J Intern Med. http://dx.doi.org/10.1111/joim.12009.
124. Smith MB, May HT, Blair TL, et al. Vitamin D excess is significantly associated with risk of atrial fibrillation. Circulation. 2011; 124:A14699.
125. Lavie CJ, Milani RV, Mehra MR, Ventura HO. Omega-3 polyunsaturated fatty acids and cardiovascular diseases. J Am Coll Cardiol. 2009;54(7):585-594.
126. Opthof T, Den Ruijter HM. Omega-3 polyunsaturated fatty acids (PUFAs or fish oils) and atrial fibrillation. Br J Pharmacol. 2007;150(3):258-260. (Pubitemid 46221034)
127. Kang JX, Leaf A. Antiarrhythmic effects of polyunsaturated fatty acids: recent studies. Circulation. 1996;94(7):1774-1780. (Pubitemid 26320288)
128. Rupp H, Rupp TP, Alter P, Maisch B. Failure of omega-3 fatty acids in atrial fibrillation? no deficiency of highly unsaturated fatty acids in the absence of heart failure. Europace. 2011; 13(9):1357.
129. Mozaffarian D, Psaty BM, Rimm EB, et al. Fish intake and risk of incident atrial fibrillation. Circulation. 2004;110(4):368-373. (Pubitemid 38993844)
130. Virtanen JK, Mursu J, Voutilainen S, Tuomainen TP. Serum long-chain n-3 polyunsaturated fatty acids and risk of hospital diagnosis of atrial fibrillation in men. Circulation. 2009;120(23): 2315-2321.
131. Brouwer IA, Heeringa J, Geleijnse JM, Zock PL, Witteman JC. Intake of very long-chain n-3 fatty acids from fish and incidence of atrial fibrillation: the Rotterdam Study. Am Heart J. 2006;151(4):857-862.
132. Liu T, Korantzopoulos P, Shehata M, Li G, Wang X, Kaul S. Prevention of atrial fibrillation with omega-3 fatty acids: a meta-analysis of randomised clinical trials. Heart. 2011; 97(13):1034-1040.
133. Macchia A, Grancelli H, Varini S, et al. Omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: results of the FORWARD (Randomized Trial to Assess Efficacy of PUFA for the Maintenance of Sinus Rhythm in Persistent Atrial Fibrillation) Trial. J Am Coll Cardiol. 2013; 61(4):463-468.
134. Armaganijan L, Lopes RD, Healey JS, Piccini JP, Nair GM, Morillo CA. Do omega-3 fatty acids prevent atrial fibrillation after open heart surgery? a meta-analysis of randomized controlled trials. Clinics (Sao Paulo). 2011;66(11): 1923-1928.
135. Mariscalco G, Sarzi Braga S, Banach M, et al. Preoperative n-3 polyunsatured fatty acids are associated with a decrease in the incidence of early atrial fibrillation following cardiac surgery. Angiology. 2010;61(7):643-650.
136. Sorice M, Tritto FP, Sordelli C, Gregorio R, Piazza L. N-3 polyunsaturated fatty acids reduces post-operative atrial fibrillation incidence in patients undergoing "on-pump" coronary artery bypass graft surgery. Monaldi Arch Chest Dis. 2011; 76(2):93-98.
137. Heidt MC, Vician M, Stracke SK, et al. Beneficial effects of intravenously administered N-3 fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a prospective randomized study. Thorac Cardiovasc Surg. 2009; 57(5):276-280.
138. Calò L, Bianconi L, Colivicchi F, et al. N-3 Fatty acids for the prevention of atrial fibrillation after coronary artery bypass surgery: a randomized, controlled trial. J Am Coll Cardiol. 2005;45(10):1723-1728. (Pubitemid 40704512)
139. Andrade JG, Macle L, Khairy P, et al. Incidence and significance of early recurrences associated with different ablation strategies for AF: a STAR-AF substudy. J Cardiovasc Electrophysiol. 2012;23(12):1295-1301.
140. Kumar S, Sutherland F, Morton JB, et al. Long-term omega-3 polyunsaturated fatty acid supplementation reduces the recurrence of persistent atrial fibrillation after electrical cardioversion. Heart Rhythm. 2012;9(4):483-491.
141. Bianconi L, Calò L, Mennuni M, et al. N-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomized, double-blind, multicentre study. Europace. 2011;13(2):174-181.
142. LOVAZA [package insert]. Research Triangle Park, NC: GlaxoSmithKline; 2012.
143. Kowey PR, Reiffel JA, Ellenbogen KA, Naccarelli GV, Pratt CM. Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomized controlled trial. JAMA. 2010;304(21):2363-2372.
144. Sawin CT, Geller A, Wolf P, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med. 1994;331(19):1249-1252. (Pubitemid 24333188)
145. Forfar JC, Miller HC, Toft AD. Occult thyrotoxicosis: a reversible cause of "idiopathic" atrial fibrillation. Am J Cardiol. 1979; 44(1):9-12. (Pubitemid 9216885)
146. Duggal J, Singh S, Barsano CP, Arora R. Cardiovascular risk with subclinical hyperthyroidism and hypothyroidism: pathophysiology and management. J Cardiometab Syndr. 2007;2(3): 198-206.
147. Auer J, Scheibner P, Mische T, Langsteger W, Eber O, Eber B. Subclinical hyperthyroidism as a risk factor for atrial fibrillation. Am Heart J. 2001;142(5):838-842. (Pubitemid 33016203)
148. Bielecka-Dabrowa A, Mikhailidis DP, Rysz J, Banach M. The mechanisms of atrial fibrillation in hyperthyroidism. Thyroid Res. 2009;2(1):4.
149. Fazio S, Palmieri EA, Lombardi G, Biondi B. Effects of thyroid hormone on the cardiovascular system. Recent Prog Horm Res. 2004;59:31-50. (Pubitemid 41327146)
150. Diker E, Aydogdu S, Ozdemir M, et al. Prevalence and predictors of atrial fibrillation in rheumatic heart disease. Am J Cardiol. 1996;77(1):96-98. (Pubitemid 26011643)
151. Schwartz R, Myerson RM, Lawrence T, Nichols HT. Mitral stenosis, massive pulmonary hemorrhage, and emergency valve replacement. N Engl J Med. 1966;275(14):755-788.
152. Qian Y, Meng J, Tang H, et al. Different structural remodelling in atrial fibrillation with different types of mitral valvular diseases. Europace. 2010;12(3):371-377.
153. Grigioni F, Avierinos JF, Ling LH, et al. Atrial fibrillation complicating the course of degenerative mitral regurgitation: determinants and long-term outcome. J Am Coll Cardiol. 2002; 40(1):84-92. (Pubitemid 34701381)
154. Shimada S. A 13-year follow-up study of rheumatic valvular diseases. Jpn Circ J. 1986;50(12):1304-1308. (Pubitemid 17018403)
155. Noble RJ, Fisch C. Factors in the genesis of atrial fibrillation in rheumatic valvular disease. Cardiovasc Clin. 1973;5(2):97-114.
156. Zhou Z, Hu D. An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China. J Epidemiol. 2008;18(5):209-216.
157. White H, Walsh W, Brown A, et al. Rheumatic heart disease in indigenous populations. Heart Lung Circ. 2010;19(5-6):273-281.
158. Sliwa K, Carrington M, Mayosi BM, Zigiriadis E, Mvungi R, Stewart S. Incidence and characteristics of newly diagnosed rheumatic heart disease in urban African adults: insights from the heart of Soweto study. Eur Heart J. 2010;31(6):719-727.
159. Widgren V, Dencker M, Juhlin T, Platonov P, Willenheimer R. Aortic stenosis and mitral regurgitation as predictors of atrial fibrillation during 11 years of follow-up. BMC Cardiovasc Disord. 2012;12(1):92.
160. Jibrini MB, Molnar J, Arora RR. Prevention of atrial fibrillation by way of abrogation of the renin-angiotensin system: a systematic review and meta-analysis. Am J Ther. 2008;15(1):36-43. (Pubitemid 351161180)
161. Disertori M, Barlera S, Staszewsky L, Latini R, Quintarelli S, Franzosi MG. Systematic review and meta-analysis: reninangiotensin system inhibitors in the prevention of atrial fibrillation recurrences: an unfulfilled hope. Cardiovasc Drugs Ther. 2012;26(1):47-54.
162. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005;45(5):712-719. (Pubitemid 40282586)
163. Schmieder RE, Kjeldsen SE, Julius S, et al. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J Hypertens. 2008;26(3):403-411. (Pubitemid 351317247)
164. Goette A, Schön N, Kirchhof P, et al. Angiotensin II-antagonist in paroxysmal atrial fibrillation (ANTIPAF) trial. Circ Arrhythm Electrophysiol. 2012;5(1):43-51.
165. Disertori M, Lombardi F, Barlera S, et al. Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial. Am Heart J. 2010;159(5):857-863.
166. Nasr IA, Bouzamondo A, Hulot JS, Dubourg O, Le Heuzey JY, Lechat P. Prevention of atrial fibrillation onset by b-blocker treatment in heart failure: a meta-analysis. Eur Heart J. 2007; 28(4):457-462. (Pubitemid 47343566)
167. Acikel S, Bozbas H, Gultekin B, et al. Comparison of the efficacy of metoprolol and carvedilol for preventing atrial fibrillation after coronary bypass surgery. Int J Cardiol. 2008;126(1): 108-113. (Pubitemid 351512361)
168. Haghjoo M, Saravi M, Hashemi MJ, et al. Optimal b-blocker for prevention of atrial fibrillation after on-pump coronary artery bypass graft surgery: carvedilol versus metoprolol. Heart Rhythm. 2007;4(9):1170-1174. (Pubitemid 47333643)
169. Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001;357(9266): 1385-1390. (Pubitemid 32455364)
170. Williams RS, deLemos JA, Dimas V, Reisch J, Hill JA, Naseem RH. Effect of spironolactone on patients with atrial fibrillation and structural heart disease. Clin Cardiol. 2011; 34(7):415-419.
171. Swedberg K, Zannad F, McMurray JJ, et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASIS-HF (Eplerenone in Mild Patients Hospitalization And Survival Study in Heart Failure) study. J Am Coll Cardiol. 2012;59(18):1598-1603.
172. Could niacin cause atrial fibrillation? A study of 147 users. eHealthMe website. http://www.ehealthme.com/ds/niacin/atrialfibrillation. Accessed February 25, 2013.